https://insightsemerge.com/press-releases/greenberg-traurig-advises-tnl-mediagene-in-management-buyout-equity-transactionInsights Emergeen2026-11-11T00:18:49.381ZGreenberg Traurig Advises TNL Mediagene in Management Buyout, Equity Transaction https://insightsemerge.com/press-releases/tigermed-to-participate-in-the-privatization-of-frontage-holdings-corporation-and-divestInsights Emergeen2026-11-10T09:10:57.509ZTigermed to Participate in the Privatization of Frontage Holdings Corporation and Divest Its Overseas Laboratory Services Business https://insightsemerge.com/roundups/business-week-of-nov-2-2026Insights Emergeen2026-11-09T14:57:00.000ZDeals and debt shape third-quarter results: the week in business https://insightsemerge.com/roundups/biotech-and-pharma-week-of-nov-2-2026Insights Emergeen2026-11-09T14:46:00.000ZQ3 results put cash runways and 2027 FDA timelines in focus https://insightsemerge.com/roundups/health-and-medical-week-of-nov-2-2026Insights Emergeen2026-11-09T14:35:00.000ZQ3 results bring raised guidance, CVS plans split: health week https://insightsemerge.com/press-releases/immunitybio-reports-label-expansion-and-additional-global-approval-with-q3-2026-netInsights Emergeen2026-11-09T13:02:59.175ZImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million https://insightsemerge.com/press-releases/compugen-reports-third-quarter-2026-resultsInsights Emergeen2026-11-09T12:23:11.021ZCompugen Reports Third Quarter 2026 Results https://insightsemerge.com/press-releases/hotspot-therapeutics-presents-preclinical-data-on-oral-small-molecule-irf5-inhibitorInsights Emergeen2026-11-09T12:15:45.821ZHotSpot Therapeutics Presents Preclinical Data on Oral Small Molecule IRF5 Inhibitor HST‑2011 at ACR Convergence 2026 https://insightsemerge.com/press-releases/johnson-and-johnson-announces-icotyder-icotrokinra-delivers-significant-improvement-inInsights Emergeen2026-11-07T15:18:46.079ZJohnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide https://insightsemerge.com/press-releases/hengrui-pharma-and-braveheart-bio-present-data-from52-week-open-label-extension-of-phaseInsights Emergeen2026-11-06T20:36:29.123ZHengrui Pharma and Braveheart Bio Present Data from52-Week Open-Label Extension of Phase 2 Studyof HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026